Katzung-15th-edition

A 14-year-old girl with asthma requiring daily corticosteroid therapy presented with:
- History of allergies to house dust mites, cats, grasses, and ragweed.
- Recent cold leading to worsening shortness of breath and wheezing.
- Clinical signs: tachycardic (pulse 120 bpm) and tachypneic (respirations 32/min).

Asthma prevalence has increased over the past 60 years, particularly affecting those under 18.
Global estimate: 300 million individuals affected by asthma.
In the U.S.:
- 17.7 million adults (7.4%) and 6.3 million children (8.6%) have asthma.
- Accounts for 10.5 million outpatient visits, 1.8 million emergency visits, and 439,000 hospitalizations yearly.
Mortality: Annual deaths around 3,500, often preventable, showing no significant improvement despite treatment advancements.
Disproportionate impact on Black Americans due to healthcare access, environmental factors, and systemic racism.

Recurrent symptoms: shortness of breath, chest tightness, wheezing, and chronic cough.
Pathophysiology involves:
- Reversible airway narrowing and airway hypersensitivity.
- Inflammation characterized by lymphocytic and eosinophilic infiltration.
- Airway remodeling may occur with chronic asthma.
- Severity classified by:
  - Impairment: Frequency and intensity of symptoms and medication need.
  - Risk: Susceptibility to exacerbations based on prior history.

Mediated by Immunoglobulin E (IgE) in response to allergens (e.g., pollen, pet dander).
IgE binds to receptors on mast cells, leading to:
- Release of mediators (histamine, leukotrienes) causing bronchoconstriction (early response).
- Late-phase response involves eosinophilic inflammation driven by cytokines (IL-4, IL-5, IL-13), causing further bronchoconstriction and mucus production.
Not all asthma is allergic; various triggers include viral infections and irritants, leading to bronchial hyperreactivity.

Bronchodilators (e.g., Beta-agonists like albuterol)
- Indications: Immediate relief during acute bronchoconstriction.
- Performance: Rapid action, may cause side effects like tachycardia.

Inhaled Corticosteroids (ICS):
- Purpose: Anti-inflammatory, reduces exacerbation frequency.
- Common agents: Beclomethasone, fluticasone, budesonide.
- Risk of systemic effects reduced via inhalation.
Long-acting Beta Agonists (LABAs):
- Indication: Maintenance therapy in conjunction with ICS.
- Not effective alone; must be used with corticosteroids.
Leukotriene Receptor Antagonists (e.g., montelukast):
- Block the action of leukotrienes which cause bronchoconstriction.

Targeting specific pathways to reduce exacerbations in severe asthma; examples include:
- Omalizumab: Anti-IgE antibody, suited for allergy-related asthma.
- Mepolizumab and Benralizumab: Target IL-5 for eosinophilic asthma management.

Immediate steps in emergency situations:
- Administer high-flow oxygen, nebulized albuterol, and consider ipratropium.
- Corticosteroids: Intravenous methylprednisolone recommended.
- Monitoring and potential escalation to intensive care for respiratory failure.

Adjust therapy based on exacerbation history and symptom control.
- Increment in inhaled corticosteroids and the introduction of LABA if symptoms persist.
- Educate patients and families on adherence and proper management techniques to prevent worsening.

Ongoing research into asthma phenotype differentiation enables personalized treatment plans.
Consideration of blood eosinophilia and other biomarkers for guiding therapy decisions.

Effective asthma management requires a combination of immediate relievers and long-term control measures, along with comprehensive education for patients. Careful monitoring and adjustment are critical for preventing exacerbations and adapting to individual patient needs.